Apurinic/apyrimidinic endonuclease/redox eff ector factor (APE1/Ref-1) is the major AP
endonuclease in mammalian cells. It is a multifunctional protein which functions not
only in DNA repair but also as a reduction-oxidation factor. Recently studies have showed that
alteration of expression levels, cellular location and/or patterns of APE1/Ref-1 may consider as
a good candidate in cancer screening and auxiliary diagnosis.
Interestingly, we found that expression of APE1/Ref-1 was signifi cantly increased in tumor
patients? serum. So we measured serum APE1/Ref-1 protein level in 210 healthy and 200 lung
cancer patients by sandwich ELISA. Serum APE1/Ref-1 protein level was skewed distribution
and signifi cant increased in cancer patients (P<0.05). We also detected serum APE1/Ref-1
antibody in 345 lung cancer patients, 350 healthy donors and 91 monitor patients before and
aft er chemotherapy by indirect ELISA. Serum APE1/Ref-1-Abs level of lung cancer patients
was signifi cantly higher than that of healthy donors and aft er chemotherapy (P=0.000). Both
of APE1/Ref-1 protein and antibody combined with CEA, CA125 and CA242 can elevate the
diagnostic sensitivity and correct rate. Th ese results indicated that detection of APE1/Ref-1 in
serum may be helpful in early diagnosis of malignant tumors and evaluating chemosensitivity.
To explore the genetic association between SNP of APE1/Ref-1 and lung cancer susceptibility,
we investigated a population based case control study among Chinese Han people in Chongqing
City. Logistic regression analysis indicated that APE1 -141G/G genotype were reduced 38%
risk of lung cancer compared with APE1 -141T/T genotype. APE1-141T/148Glu haplotype may
serves as an important genetic susceptibility factor for lung cancer.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals